News

Sejelas Founder-CEO Interview with Simon Mølgaard

Our CEO Simon Mølgaard was interviewed by Sejelas where he talks about Teitur Trophics and our commitment to developing novel treatments for treating patients suffering from neurodegenerative diseases. You can read the full interview…
Read more

Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases

  • Financing co-led by Sunstone Life Science Ventures and Sound Bioventures with participation from Industrifonden, Innovestor’s Life Science Fund and P53 Invest
  • Discovery of a novel mechanism with the potential to prevent the death of neurons in neurodegenerative diseases
  • First-in-Class, lead drug candidate advances into clinical development in a Phase 1b study
  Aarhus, Denmark March 14th, 2023: Teitur Trophics (“Teitur”), a biotech company dedicated to developing new treatments for patients suffering from neurodegenerative diseases, today announces the completion of a €28M Series A financing. The…
Read more